How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
GM1 Gangliosidosis Treatment Market
- By Treatment Type: Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT), Gene Therapy, Hematopoietic Stem Cell Transplantation (HSCT), Supportive and Symptomatic Care
- By Patient Age Group: Infantile GM1 Gangliosidosis, Juvenile GM1 Gangliosidosis, Adult-Onset GM1 Gangliosidosis
- By Disease Severity: Early-Onset Severe, Late-Onset Mild to Moderate, Chronic Progressive
- By Delivery Method: Intravenous Infusion, Intrathecal Injection, Intracerebral Administration
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Enzyme Replacement Therapy (ERT) leads By Treatment Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 10 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 256 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.161 →
- 11 Company Profiles 10 players: SWOT & benchmarking p.169 →
Full report · locked preview
Everything inside the GM1 Gangliosidosis Treatment Market report
A complete, evidence-based study - 11 chapters and 107 sections covering market size, segmentation across 4 axes, regional analysis and 10 company profiles, forecast to 2033.
Segmentation covered
Treatment Type 5
Patient Age Group 3
Disease Severity 3
Delivery Method 3
Companies profiled
Astellas Pharma Inc.
Orchard Therapeutics plc
Sangamo Therapeutics Inc.
Ultragenyx Pharmaceutical Inc.
Avrobio Inc.
MeiraGTx Holdings plc
REGENXBIO Inc.
Bluebird Bio Inc.
Pfizer Inc.
Sanofi S.A.
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
10 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Astellas Pharma Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Orchard Therapeutics plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Sangamo Therapeutics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Ultragenyx Pharmaceutical Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Avrobio Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.178 →MeiraGTx Holdings plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →REGENXBIO Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Bluebird Bio Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Pfizer Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.202 →Sanofi S.A.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$6,263M by 2033 · 10.9% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Enzyme Replacement Therapy (ERT)45.4
- Substrate Reduction Therapy (SRT)11.8
- Gene Therapy18.3
- Hematopoietic Stem Cell Transplantation (HSCT)15.6
- Supportive and Symptomatic Care8.8
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$900.7M → $2,268M · 12.2%
Europe$627.8M → $1,472M · 11.2%
Asia Pacific$573.2M → $1,284M · 10.6%
Latin America$354.8M → $907.1M · 12.4%
Middle East and Africa$272.9M → $670.1M · 11.9%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.902026
10.902027
10.912028
10.932029
10.942030
10.952031
10.972032
10.982033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Astellas Pharma Inc.26.5
- Orchard Therapeutics plc13.7
- Sangamo Therapeutics Inc.6.4
- Ultragenyx Pharmaceutical Inc.10.5
- Avrobio Inc.10.5
- MeiraGTx Holdings plc4.4
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Treatment Type24.7%
Patient Age Group25.5%
Disease Severity32.6%
Delivery Method17.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.4
- Europe22.3
- Asia Pacific19.4
- Latin America13.7
- Middle East and Africa10.2
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Astellas Pharma Inc. | 91 | 98 | 84 | 90 | 81 | 92 | 89 |
| Orchard Therapeutics plc | 93 | 79 | 82 | 90 | 88 | 71 | 84 |
| Sangamo Therapeutics Inc. | 64 | 78 | 86 | 67 | 63 | 83 | 74 |
| Ultragenyx Pharmaceutical Inc. | 79 | 61 | 67 | 74 | 82 | 59 | 70 |
| Avrobio Inc. | 71 | 62 | 70 | 58 | 64 | 76 | 67 |
| MeiraGTx Holdings plc | 71 | 53 | 68 | 70 | 55 | 63 | 63 |
| REGENXBIO Inc. | 40 | 47 | 46 | 40 | 51 | 54 | 46 |
| Bluebird Bio Inc. | 56 | 40 | 46 | 37 | 49 | 35 | 44 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Astellas Pharma Inc.
- Orchard Therapeutics plc
- Sangamo Therapeutics Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Astellas Pharma Inc. | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Orchard Therapeutics plc | ✓ | ✓ | ◐ | ✓ | ✓ | ◐ |
| Sangamo Therapeutics Inc. | ◐ | ✓ | ✓ | ◐ | ◐ | ✓ |
| Ultragenyx Pharmaceutical Inc. | ◐ | − | ◐ | ◐ | ✓ | − |
| Avrobio Inc. | ✓ | ✓ | ◐ | ◐ | ◐ | ✓ |
| MeiraGTx Holdings plc | ✓ | − | − | ◐ | ◐ | ◐ |
| REGENXBIO Inc. | − | ◐ | − | − | − | − |
| Bluebird Bio Inc. | ◐ | ◐ | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Astellas Pharma Inc.89
2Orchard Therapeutics plc84
3Sangamo Therapeutics Inc.74
4Ultragenyx Pharmaceutical Inc.70
5Avrobio Inc.67
6MeiraGTx Holdings plc63
7REGENXBIO Inc.46
8Bluebird Bio Inc.44
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Astellas Pharma Inc.Orchard Therapeutics plc
Challenger3
Strong scale, closing on the leaders.
Sangamo Therapeutics Inc.Ultragenyx Pharmaceutical Inc.Avrobio Inc.
Contender1
Focused players with pockets of strength.
MeiraGTx Holdings plc
Niche2
Specialists in a single segment or region.
REGENXBIO Inc.Bluebird Bio Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Treatment Type in North America, then scale across GM1 Gangliosidosis Treatment Market — a $313M beachhead inside a $5.73B market.
Beachhead (SOM)$313Mobtainable near-term
Serviceable (SAM)$2.14Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Enzyme Replacement Therapy (ERT)
Best fit — highest urgency & budget in Treatment Type.
Economic buyer75 fit
Substrate Reduction Therapy (SRT)
Strong fit — clear ROI and a fast path to value.
End user64 fit
Gene Therapy
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Treatment Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Patient Age Group & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Disease Severity
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel31%
Digital / self-serve19%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Treatment Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win GM1 Gangliosidosis Treatment Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified41%
Sales qualified21%
Evaluation14%
Closed-won5%
$8.8KCAC
$33KLTV
3.7:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
GM1 Gangliosidosis Treatment Market is a durable-growth opportunity — $6.31B by 2033, compounding at 7.5%.
TAM · 2025$3.55Btoday
TAM · 2033$6.31Bforecast
CAGR7.5%2027–2033
Cumulative$43.4Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$6.31BTotal addressable market
SAM$2.26BServiceable available market
SOM$377MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.5% CAGR
Demand compounds through 2033, outpacing GDP across Treatment Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Treatment Type moving from early to mainstream — durable secular demand.
Consolidation upside
10+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$6.31BLarge & growingTAM by 2033 at 7.5% CAGR
$2.26BServiceable nowreachable with today’s model
$377MBeachhead winobtainable near-term share
10+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.93BBear4.8% CAGR
$6.31BBase7.5% CAGR
$8.08BBull9.8% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Patient Age Group optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
GM1 Gangliosidosis Treatment Market — a $6.33B market by 2033. Plan: grow share from 6.3% to 11.8%.
Market size · 2033$6.33Btotal addressable
Market CAGR3.8%2027–2033
Target share11.8%from 6.3% today
Revenue ambition$747Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.3% | 11.8% | Behind |
| Revenue | $427M | $747M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 33.5% | 44.5% | Ahead |
| Customer retention | 88.7% | 94.9% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Treatment Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Patient Age Group capability
A defensible second engine — invest in Patient Age Group to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Treatment Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Patient Age Group
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $99M capacity & capability investment
- Greenlight bolt-on M&A in Patient Age Group
- Authorise North America expansion plan
- Fund R&D program for Treatment Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossBehind
- Input-cost & supply riskAt risk
- Regulatory / policy changeOn track
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the GM1 Gangliosidosis Treatment Market conversation — a $2.22B market you can size, segment and defend in minutes.
Market size · 2033$2.22Btotal opportunity
Growth11.2%CAGR to 2033
Addressable buyers1,240+accounts in scope
Typical ROI5.2×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Treatment Type
Goal Grow share in Treatment Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.2×return on cost, year one
< 2 mopayback period
$88K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
10+players profiled in this market
Coverage includes
Astellas Pharma Inc.Orchard Therapeutics plcSangamo Therapeutics Inc.Ultragenyx Pharmaceutical Inc.Avrobio Inc.MeiraGTx Holdings plcREGENXBIO Inc.Bluebird Bio Inc.+2 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your GM1 Gangliosidosis Treatment Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
GM1 Gangliosidosis Treatment Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Portable Oxygen Generator Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportGly-His-Lys Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportGlycyrrhizine Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportGlycyrrhizic Acid Powder Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportGlycyrrhizic Acid Glycosides Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportGlycyrrhizic Acid and Its Derivatives Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportGlycyrrhizic Acid 98% Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportGlycyrrhiza Inflata Root Extract Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportGlycyrrhiza Glabra Root Extract Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportGlycyrrhetinic Acid Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportGlycyrrhetic Acid Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportGlycyl-L-Tyrosine Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.